Fortress Biotech has been granted a patent for antibodies and fragments that bind to human PD-L1, potentially treating cancer by slowing its progression. The method involves administering these novel antibodies with specific CDRs to cancer patients. GlobalData’s report on Fortress Biotech gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Fortress Biotech Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Fortress Biotech, Quantum cryptography was a key innovation area identified from patents. Fortress Biotech's grant share as of January 2024 was 49%. Grant share is based on the ratio of number of grants to total number of patents.

Treatment of cancer using antibodies binding to pd-l1

Source: United States Patent and Trademark Office (USPTO). Credit: Fortress Biotech Inc

A recently granted patent (Publication Number: US11834505B2) discloses a method for treating cancer by administering an antibody or fragment thereof that binds to human programmed death-ligand 1 (PD-L1). The antibody includes specific sequences in its heavy and light chains, targeting various types of cancer such as lung cancer, melanoma, renal cell carcinoma (RCC), head and neck cancer, or bladder cancer. The method also allows for the administration of additional therapeutic compounds like CAR-T cells, tumor-targeting antibodies, immune response potentiating modalities, or small molecule drugs to enhance treatment efficacy.

Furthermore, the patent claims specify the sequences of the heavy and light chains of the antibody, emphasizing their role in targeting PD-L1 in different types of cancer. The method outlined in the patent covers a range of cancer types, including non-small cell lung cancer (NSCLC), carcinoma, melanoma, RCC, head and neck cancer, and bladder cancer. By utilizing specific sequences in the antibody structure, the treatment method aims to effectively bind to PD-L1 and potentially improve outcomes for cancer patients. The patent also highlights the option to combine the antibody treatment with other therapeutic compounds for a comprehensive approach to cancer treatment, showcasing a promising avenue for future research and development in the field.

To know more about GlobalData’s detailed insights on Fortress Biotech, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies